What Analysts Are Saying About Arcus Biosciences Stock
Benzinga Insights 9 months ago
Analyst Ratings
Ratings for Arcus Biosciences (NYSE:RCUS) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 0 | 3 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 1 | 0 | 0 |
| 3M Ago | 1 | 0 | 1 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $25.8, a high estimate of $32.00, and a low estimate of $20.00. This current average has increased by 13.16% from the previous average price target of $22.80.
Diving into Analyst Ratings: An In-Depth Exploration
A clear picture of Arcus Biosciences's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Eva Fortea Verdejo | Wells Fargo | Lowers | Equal-Weight | $23.00 | $30.00 |
| Richard Law | Goldman Sachs | Raises | Buy | $28.00 | $16.00 |
| Terence Flynn | Morgan Stanley | Lowers | Equal-Weight | $20.00 | $23.00 |
| Emily Bodnar | HC Wainwright & Co. | Raises | Buy | $32.00 | $28.00 |
| Jason Zemansky | B of A Securities | Raises | Neutral | $26.00 | $17.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Arcus Biosciences. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Arcus Biosciences compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Arcus Biosciences's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Arcus Biosciences's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Arcus Biosciences analyst ratings.
Discovering Arcus Biosciences: A Closer Look
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Financial Insights: Arcus Biosciences
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Challenges: Arcus Biosciences's revenue growth over 3M faced difficulties. As of 30 September, 2025, the company experienced a decline of approximately -45.83%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -519.23%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -27.41%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -13.18%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Arcus Biosciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.25.
What Are Analyst Ratings?
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.